Samuel Mamane1, Louis Mullie1, Nicolo Piazza2, Giuseppe Martucci2, José Morais3, Antonio Vigano4, Mark Levental5, Kristoff Nelson1, Ruediger Lange6, Jonathan Afilalo7. 1. Department of Medicine, McGill University, Montreal, Quebec, Canada. 2. Department of Medicine, McGill University, Montreal, Quebec, Canada; Division of Cardiology, McGill University, Montreal, Quebec, Canada. 3. Department of Medicine, McGill University, Montreal, Quebec, Canada; Division of Geriatric Medicine, McGill University, Montreal, Quebec, Canada. 4. Department of Anesthesia, McGill University, Montreal, Quebec, Canada. 5. Department of Radiology, McGill University, Montreal, Quebec, Canada. 6. Division of Cardiac Surgery, German Heart Center, Munich, Germany. 7. Department of Medicine, McGill University, Montreal, Quebec, Canada; Division of Cardiology, McGill University, Montreal, Quebec, Canada; Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. Electronic address: jonathan.afilalo@mcgill.ca.
Abstract
BACKGROUND: Psoas muscle area (PMA) is a novel measure of frailty that can be efficiently measured from computed tomography images to help predict risk in older adults referred for transcatheter aortic valve replacement (TAVR). The objective of this study was to determine if PMA would be incrementally predictive of mortality and morbidity after TAVR. METHODS: The pre-TAVR computed tomography scans of 208 consecutive patients at 2 hospitals in Montreal and Munich were analyzed to measure the cross-sectional area of the left and right psoas muscles on a single axial slice at the level of L4. The primary outcome was all-cause mortality assessed according to sex-stratified Cox regression models adjusted for the Society of Thoracic Surgeons predicted risk of mortality. RESULTS: The mean age was 80.7 ± 6.8 years with 55% women and a total of 57 deaths over a mean follow-up of 504 days. PMA was lower in nonsurvivors compared with survivors among women (12.9 vs 14.5 cm(2); P = 0.047) but not men (21.7 vs 22.4 cm(2); P = 0.50). The association between PMA and all-cause mortality in women persisted after adjustment for Society of Thoracic Surgeons risk (hazard ratio, 0.88 per cm(2); 95% confidence interval, 0.78-0.99). An association between PMA and bleeding complications was seen in men (odds ratio, 0.78; 95% confidence interval, 0.62-0.97). Sensitivity analyses with PMA normalized to body mass index yielded similar results. CONCLUSIONS: This study has shown that PMA is a marker of frailty associated with midterm survival in women who undergo TAVR. Further research is warranted to pursue PMA as a prognostic marker and therapeutic target in this vulnerable population.
BACKGROUND: Psoas muscle area (PMA) is a novel measure of frailty that can be efficiently measured from computed tomography images to help predict risk in older adults referred for transcatheter aortic valve replacement (TAVR). The objective of this study was to determine if PMA would be incrementally predictive of mortality and morbidity after TAVR. METHODS: The pre-TAVR computed tomography scans of 208 consecutive patients at 2 hospitals in Montreal and Munich were analyzed to measure the cross-sectional area of the left and right psoas muscles on a single axial slice at the level of L4. The primary outcome was all-cause mortality assessed according to sex-stratified Cox regression models adjusted for the Society of Thoracic Surgeons predicted risk of mortality. RESULTS: The mean age was 80.7 ± 6.8 years with 55% women and a total of 57 deaths over a mean follow-up of 504 days. PMA was lower in nonsurvivors compared with survivors among women (12.9 vs 14.5 cm(2); P = 0.047) but not men (21.7 vs 22.4 cm(2); P = 0.50). The association between PMA and all-cause mortality in women persisted after adjustment for Society of Thoracic Surgeons risk (hazard ratio, 0.88 per cm(2); 95% confidence interval, 0.78-0.99). An association between PMA and bleeding complications was seen in men (odds ratio, 0.78; 95% confidence interval, 0.62-0.97). Sensitivity analyses with PMA normalized to body mass index yielded similar results. CONCLUSIONS: This study has shown that PMA is a marker of frailty associated with midterm survival in women who undergo TAVR. Further research is warranted to pursue PMA as a prognostic marker and therapeutic target in this vulnerable population.
Authors: Britta Larsen; John Bellettiere; Matthew Allison; Robyn L McClelland; Iva Miljkovic; Chantal A Vella; Pamela Ouyang; Kimberly R De-Guzman; Michael Criqui; Jonathan Unkart Journal: Metabolism Date: 2020-07-23 Impact factor: 8.694
Authors: Louis Koizia; Mitesh Naik; George Peck; Ghada W Mikhail; Sayan Sen; Iqbal S Malik; Ben Ariff; Michael B Fertleman Journal: Curr Gerontol Geriatr Res Date: 2020-06-28
Authors: Iris J G Rutten; Jorne Ubachs; Roy F P M Kruitwagen; Regina G H Beets-Tan; Steven W M Olde Damink; Toon Van Gorp Journal: J Cachexia Sarcopenia Muscle Date: 2017-05-16 Impact factor: 12.910
Authors: Martijn S van Mourik; Yvonne C Janmaat; Floortje van Kesteren; Jeroen Vendrik; R Nils Planken; Marieke J Henstra; Juliëtte F Velu; Wieneke Vlastra; Aeilko H Zwinderman; Karel T Koch; Robbert J de Winter; Joanna J Wykrzykowska; Jan J Piek; José P S Henriques; Vincent R Lanting; Jan Baan; Corine Latour; Robert Lindeboom; M Marije Vis Journal: Catheter Cardiovasc Interv Date: 2018-09-12 Impact factor: 2.692
Authors: Luigi Castaldo; Federica Laguzzi; Rona J Strawbridge; Damiano Baldassarre; Fabrizio Veglia; Lorenzo Vigo; Elena Tremoli; Ulf de Faire; Per Eriksson; Andries J Smit; Jiri Aubrecht; Karin Leander; Matteo Pirro; Philippe Giral; Alberto Ritieni; Giovanni Di Minno; Anders Mälarstig; Bruna Gigante Journal: Genes (Basel) Date: 2020-10-22 Impact factor: 4.096